AIM ImmunoTech Inc. (NYSE: AIM)

Sector: Healthcare Industry: Biotechnology CIK: 0000946644
Market Cap 894,444.70
P/B -0.15
P/E -0.06
P/S 7.99
ROIC (Qtr) 389.49
Div Yield % 0.00
Rev 1y % (Qtr) -25.71
Total Debt (Qtr) 2.34 Mn
Debt/Equity (Qtr) -0.38
Add ratio to table...

About

AIM ImmunoTech Inc., often recognized by its stock symbol AIM, operates in the life sciences industry, specifically focusing on the development and commercialization of therapeutic products. Its primary focus is on the treatment of cancer and other diseases, with two main products at the forefront: Ampligen and Oncolytic Virus. The company's operations span across various business segments. The Biologics segment is dedicated to the development and commercialization of biologics, such as Ampligen and Oncolytic Virus. Ampligen, a therapeutic agent,...

Read more

Investment thesis

Bull case

  • Retained earnings of (436.61M) represent substantial 71.85x of equity (6.08M), indicating strong internal capital generation.
  • Tangible assets of 3.45M provide robust 5.09x coverage of other current liabilities 679000, indicating strong asset backing.
  • Strong cash position of 2.35M provides 3.46x coverage of other current liabilities 679000, indicating excellent liquidity.
  • Robust R&D investment of 4.53M at 0.45x of SG&A 10.06M demonstrates strong commitment to innovation and future growth.
  • Strong R&D investment of 4.53M at 15.99x of capex 283000 shows balanced investment in innovation and infrastructure.

Bear case

  • Operating cash flow of (12.93M) barely covers its investment activities of 5.65M, with a coverage ratio of -2.29, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of 5.65M provide weak support for R&D spending of 4.53M, which is 1.25x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (12.93M) shows concerning coverage of stock compensation expenses of 256000, with a -50.49 ratio indicating potential earnings quality issues.
  • Free cash flow of (13.21M) provides weak coverage of capital expenditures of 283000, with a -46.67 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (15.20M) show weak coverage of depreciation charges of 675000, with a -22.51 ratio indicating high capital intensity and potential reinvestment needs.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.59 11.06
EV to Cash from Ops. EV/CFO -0.25 26.32
EV to Debt EV to Debt 1.38 762.61
EV to EBIT EV/EBIT -0.21 -13.49
EV to EBITDA EV/EBITDA -0.23 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -0.24 25.66
EV to Market Cap EV to Market Cap 3.60 203.37
EV to Revenue EV/Rev 28.78 156.31
Price to Book Value [P/B] P/B -0.15 20.59
Price to Earnings [P/E] P/E -0.06 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) -27.48 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 25.53 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 156.50 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 35.27 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 48.86 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) 35.27 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) 34.18 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) 56.91 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) 37.31 -40.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) -88.96 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.02 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 0.58 3.92
Current Ratio Curr Ratio (Qtr) 0.64 7.33
Debt to Equity Ratio Debt/Equity (Qtr) -0.38 0.48
Interest Cover Ratio Int Coverage (Qtr) -27.48 956.66
Times Interest Earned Times Interest Earned (Qtr) -27.48 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -12,966.10 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) -13,568.75 -18,246.34
EBT Margin % EBT Margin % (Qtr) -14,062.50 -19,108.08
Gross Margin % Gross Margin % (Qtr) 15.20 -10.30
Net Profit Margin % Net Margin % (Qtr) -14,062.50 -19,056.96